tiprankstipranks
BrainCool AB (SE:BRAIN)
:BRAIN
Want to see SE:BRAIN full AI Analyst Report?

BrainCool AB (BRAIN) AI Stock Analysis

0 Followers

Top Page

SE:BRAIN

BrainCool AB

(BRAIN)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 5.2)
Rating:45Neutral
Price Target:
kr0.73
▲(25.86% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by persistent losses and ongoing cash burn, with recent revenue momentum also softening. This is partly offset by a low-leverage balance sheet (zero debt and meaningful equity) and relatively neutral technical signals that do not indicate extreme momentum in either direction.
Positive Factors
Conservative balance sheet
Zero reported debt and substantial equity materially reduce solvency risk and extend optionality for a medical device company. This conservatism supports funding commercialization, R&D, or working capital without immediate refinancing pressure, improving medium-term resilience.
Negative Factors
Persistently negative cash flow
Consistent, large negative operating and free cash flow indicate ongoing cash burn that will require external financing or meaningful operational change. This undermines runway, limits investment capacity, and risks equity dilution or constrained execution over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Zero reported debt and substantial equity materially reduce solvency risk and extend optionality for a medical device company. This conservatism supports funding commercialization, R&D, or working capital without immediate refinancing pressure, improving medium-term resilience.
Read all positive factors

BrainCool AB (BRAIN) vs. iShares MSCI Sweden ETF (EWD)

BrainCool AB Business Overview & Revenue Model

Company Description
BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatmen...
How the Company Makes Money
BrainCool makes money primarily by selling and/or leasing its temperature-management medical device systems and by generating recurring revenue from associated single-use or consumable components used with those systems (where applicable). Revenue...

BrainCool AB Financial Statement Overview

Summary
Overall fundamentals are weak. The company remains deeply unprofitable with negative operating and net results across periods, and cash flow is consistently negative (TTM operating cash flow and free cash flow both materially negative). A key offset is a conservatively levered balance sheet with zero reported debt and substantial equity, which reduces near-term solvency risk.
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue36.02M36.21M39.96M23.23M17.59M9.26M
Gross Profit-16.61M-40.88M13.13M12.12M-46.16M-48.93M
EBITDA-30.83M-29.99M-34.06M-49.86M-35.07M-32.16M
Net Income-36.81M-37.05M-44.04M-61.28M-45.61M-38.75M
Balance Sheet
Total Assets177.67M192.38M162.04M133.28M133.67M99.35M
Cash, Cash Equivalents and Short-Term Investments51.40M39.57M31.40M25.06M41.21M13.58M
Total Debt0.000.000.000.000.0035.00M
Total Liabilities10.21M16.58M16.11M21.54M17.44M54.12M
Stockholders Equity167.46M175.80M145.93M111.74M116.23M45.23M
Cash Flow
Free Cash Flow-52.11M-56.49M-70.20M-67.23M-53.67M-35.06M
Operating Cash Flow-49.36M-52.68M-62.64M-61.16M-46.27M-24.25M
Investing Cash Flow-3.06M-6.54M-7.57M-6.17M-7.59M-10.82M
Financing Cash Flow95.46M67.33M76.80M50.93M81.28M36.39M

BrainCool AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.58
Price Trends
50DMA
0.69
Positive
100DMA
0.61
Positive
200DMA
0.71
Positive
Market Momentum
MACD
0.02
Positive
RSI
58.95
Neutral
STOCH
68.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BRAIN, the sentiment is Positive. The current price of 0.58 is below the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.69, and below the 200-day MA of 0.71, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 58.95 is Neutral, neither overbought nor oversold. The STOCH value of 68.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BRAIN.

BrainCool AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
kr1.21B19.506.93%-8.92%-8.33%
55
Neutral
kr428.92M-5.61-27.25%-4.08%1.31%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
kr546.68M-25.75-2.52%-10.66%73.69%
49
Neutral
kr986.42M-61.68-4.42%4.66%27.83%
46
Neutral
kr303.30M-8.89-104.38%26.25%43.03%
45
Neutral
kr319.06M-7.16-27.22%-14.57%16.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:BRAIN
BrainCool AB
0.81
-0.71
-46.70%
SE:BACTI.B
Bactiguard Holding AB
15.90
-19.60
-55.21%
SE:CRAD.B
C-Rad AB Class B
35.70
3.50
10.87%
SE:ACARIX
Acarix AB
0.27
0.04
16.59%
SE:SEDANA
Sedana Medical AB
9.79
-3.03
-23.63%
SE:MNTC
Mentice AB
15.40
0.72
4.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 15, 2026